Cintas CapEx decreased by 14.5% to $90.90M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 9.0%, from $99.92M to $90.90M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 29.9% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $43.06M | $48.75M | $59.88M | $57.22M | $74.82M | $70.02M | $76.39M | $77.71M | $106.99M | $106.70M | $93.83M | $107.03M | $101.91M | $92.92M | $101.42M | $99.92M | $114.62M | $101.96M | $106.25M | $90.90M |
| QoQ Change | — | +13.2% | +22.8% | -4.4% | +30.8% | -6.4% | +9.1% | +1.7% | +37.7% | -0.3% | -12.1% | +14.1% | -4.8% | -8.8% | +9.1% | -1.5% | +14.7% | -11.1% | +4.2% | -14.5% |
| YoY Change | — | — | — | — | +73.8% | +43.6% | +27.6% | +35.8% | +43.0% | +52.4% | +22.8% | +37.7% | -4.7% | -12.9% | +8.1% | -6.6% | +12.5% | +9.7% | +4.8% | -9.0% |
| Segment | FY'21 | FY'22 |
|---|---|---|
| All Other | $5.07M | $14.46M |
| Total | $143.47M | $240.67M |
All segment values are derived from annual filings.